Stemline Has What It Takes On EU Fast-Track Front
Executive Summary
There's good news for Stemline Therapeutics on the EU fast-track front. At least three other companies, though, have had their requests rejected in recent months and Novartis is not saying whether a request it made was successful or not.
You may also be interested in...
Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
EU Accelerated Assessment Tracker: Nine Definites So Far From 24 Requests In 2018
In 2018, the European Medicines Agency considered 24 requests from drug companies for fast-track review of their planned marketing authorization applications. The agency has granted at least nine requests, eleven have been rejected and the results of four have yet to be disclosed.
Why Advicenne's Kidney Disease Drug Reverted To Standard EU Review
The CEO of French firm Advicenne explains why the company did not win an accelerated EU assessment for its kidney disease drug ADV7103, and why it may well try again in future with another indication – and perhaps with other new drugs too.